ReviewDrugs2016
Sumatriptan/Naproxen Sodium: A Review in Migraine.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 32 citations in OpenAlex.
- Mechanochemistry-Driven Borrowing Hydrogen Processes for Ru-Catalyzed N-Alkylation: A Pathway to Enhanced Sustainability and Efficiency.Angewandte Chemie (International ed. in English) · 2025Article
- Biotransformation of Sumatriptan byMolecules (Basel, Switzerland) · 2024Article
- Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS pharmacology & translational science · 2024Review
- The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.Pain and therapy · 2023Review
- Xiongshao Zhitong Recipe Attenuates Nitroglycerin-Induced Migraine-Like BehaviorsFrontiers in pharmacology · 2022Article
- Competitive Protein Binding Assay of Naproxen by Human Serum Albumin Functionalized Silicon Dioxide Nanoparticles.Molecules (Basel, Switzerland) · 2019Article
- Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.Journal of pain research · 2018Review
- Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sumatriptan/naproxen sodium (Treximet®) is a fixed-dose combination of a serotonin 5-HT1B/1D receptor agonist (sumatriptan) and an NSAID (naproxen sodium), approved in the USA for the acute treatment of migraine with or without aura in adolescents and adults. In a randomized, phase 3 trial in adolescents, significantly more sumatriptan/naproxen sodium than placebo recipients were pain-free at 2 h. Similarly, in a pair of randomized phase 3 trials in adults, significantly more sumatriptan/naproxen sodium than placebo recipients had relief from migraine symptoms at 2 h, and the combination was more effective than individual components in terms of sustained (2-24 h) pain-free response rate. Sumatriptan/naproxen sodium was generally well tolerated, with ≤11 % of adolescents and ≤22 % of adults reporting treatment-related adverse events in the key clinical trials. The most common adverse reactions were nasopharyngitis, hot flushes and muscle tightness in adolescents, and dizziness, pain or pressure sensations, nausea, somnolence, dry mouth, dyspepsia and paraesthesia in adults. Based on current data, sumatriptan/naproxen sodium is a useful option for the acute treatment of migraine in adolescents and adults. The fixed-dose combination may reduce pill burden and improve adherence in some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.